Cargando…
Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients
BACKGROUND: Most patients with metastatic non-small cell lung cancer (NSCLC) will face treatment with systemic therapy. Current clinical studies are demonstrating improvements in chemotherapy and overall survival. However, it remains unclear whether these results are translated into clinical practic...
Autores principales: | Reinmuth, Niels, Payer, Nadine, Muley, Thomas, Hoffmann, Hans, Herth, Felix JF, Villalobos, Matthias, Thomas, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878319/ https://www.ncbi.nlm.nih.gov/pubmed/24351122 http://dx.doi.org/10.1186/1465-9921-14-139 |
Ejemplares similares
-
Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
por: Schneider, Marc A., et al.
Publicado: (2018) -
New data: new options for front-line therapy in NSCLC?
por: Reinmuth, Niels
Publicado: (2018) -
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019) -
POS-493 Predictors of Mortality in Chronic Hemodialysis Patients with COVID-19 at National Kidney and Transplant Institute: A Retrospective Cohort Study
por: ROLDAN, M.K.
Publicado: (2021) -
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)